文献速递类风湿关节炎

基于登记资料的观察性研究:早期类风湿关节炎患者炎症缓解、正式治疗目标与改善病情抗风湿药使用之间的关联

Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis.
PubMed 文献 · RMD Open · 2023-01-01

在瑞典风湿病质量登记中纳入新诊断的早期类风湿关节炎患者共11784例,评估炎症缓解与正式治疗目标(DAS28缓解<2.6)之间的关联,以及未达DAS28目标者启动新改善病情抗风湿药的可能性。炎症缓解但未达DAS28缓解者在6、12、24个月启动新药的风险比分别为1.59、1.52、1.47。

要点

  • 早期类风湿关节炎患者中,炎症缓解但未达DAS28缓解者分别占20%、22%、20%、19%。
  • 炎症缓解但未达DAS28缓解者启动新改善病情抗风湿药的风险比在6个月为1.59、12个月为1.52、24个月为1.47。
  • 早期类风湿关节炎患者中,尽管炎症缓解但未达正式治疗目标的情况常见,且与启动新改善病情抗风湿药的可能性增加相关。

核心结论

  • 在早期类风湿关节炎患者中,尽管炎症缓解但未达正式治疗目标的情况常见,且与启动新改善病情抗风湿药治疗的可能性增加相关。

研究设计与样本

  • 基于瑞典风湿病质量登记(Swedish Rheumatology Quality Register)的观察性研究,纳入新诊断类风湿关节炎患者共11784例。
  • 在类风湿关节炎诊断时及之后3、6、12、24个月评估DAS28和改善病情抗风湿药治疗。
  • 炎症缓解定义为肿胀关节数(0-28)=0且C反应蛋白<10 mg/L且红细胞沉降率正常;主要治疗目标为DAS28缓解(<2.6)。
  • 在每个随访点评估炎症缓解但未达DAS28目标的患者比例,并与炎症缓解且达到治疗目标的患者比较启动新改善病情抗风湿药的可能性,使用改良泊松回归估计率比(RR)及95%CI。

主要发现

  • 总体而言,3、6、12、24个月时处于炎症缓解的患者比例分别为34%、39%、44%、47%。
  • 在上述炎症缓解患者中,未达DAS28缓解的比例分别为20%、22%、20%、19%。
  • 炎症缓解但未达DAS28缓解的患者启动新改善病情抗风湿药治疗的可能性更高:6个月RR=1.59(95%CI 1.29至1.96),12个月RR=1.52(95%CI 1.23至1.87),24个月RR=1.47(95%CI 1.20至1.80)。

关键数值与推荐

  • 炎症缓解定义:肿胀关节数(0-28)=0且C反应蛋白<10 mg/L且红细胞沉降率正常。
  • 主要治疗目标:DAS28缓解(<2.6)。
  • 启动新改善病情抗风湿药治疗的率比:6个月RR=1.59(95%CI 1.29至1.96),12个月RR=1.52(95%CI 1.23至1.87),24个月RR=1.47(95%CI 1.20至1.80)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess associations between inflammatory remission, formal treatment targets and the likelihood of starting a new disease-modifying antirheumatic drug (DMARD), among patients with early rheumatoid arthritis (RA). METHODS: Patients newly diagnosed with RA were identified in the Swedish Rheumatology Quality Register (n=11 784). Disease Activity Score 28 (DAS28) and DMARD-treatment were assessed at RA diagnosis and 3, 6, 12 and 24 months thereafter. Inflammatory remission was defined as: swollen joints (0-28)=0 and C reactive protein <10 mg/L and normal erythrocyte sedimentation rate. The primary treatment target was DAS28 remission (<2.6). The proportion of patients in inflammatory remission who failed to reach DAS28 targets was assessed at each follow-up visit, and their likelihood of starting a new DMARD was compared with patients in inflammatory remission who reached the treatment target. rate ratios (RR) and 95% CIs were estimated with modified Poisson regression. RESULTS: Overall, 34%, 39%, 44% and 47% were in inflammatory remission at 3, 6, 12 and 24 months. Among these, 20%, 22%, 20% and 19%, respectively, failed to reach DAS28 remission. Patients who failed to reach DAS28 remission despite being in inflammatory remission were more likely to start a new DMARD treatment (RR (95% CI) at 6 months=1.59 (1.29 to 1.96), 12 months=1.52 (1.23 to 1.87)) and 24 months=1.47 (1.20 to 1.80). CONCLUSION: Failing to reach formal treatment targets, despite being in inflammatory remission, is common among patients with early RA, and is associated with an increased likelihood of starting a new DMARD-treatment.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Lindqvist J, Askling J, Lampa J, et al. Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis. RMD Open. 2023. PMID: 37973534. doi:10.1136/rmdopen-2023-003111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。